

5 June 2017

## NOTICE UNDER SECTION 708AA(2)(f) OF THE CORPORATIONS ACT 2001

Cyclopharm Limited (**Company**) is conducting a fully underwritten non-renounceable pro-rata entitlement offer to raise approximately \$7 million, before offer costs (**Entitlement Offer**).

The Entitlement Offer will be open to shareholders of the Company with a registered address in Australia, New Zealand and the United Kingdom (**Eligible Shareholders**).

Under the Entitlement Offer, Eligible Shareholders can subscribe for 1 fully paid ordinary share (**New Share**) for every 6.8 existing shares in the Company held as at 7pm (Sydney time) on Thursday, 8 June 2017 (**Record Date**) at an issue price of \$0.80 per New Share.

The Company advises that it will offer the New Shares for issue to investors under Part 6D.2 of the Corporations Act 2001 (**Act**) and states that this notice is given to ASX under paragraph 708AA(2)(f) of the Act, as modified by ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84.

Accordingly, the Company advises:

- 1 The Company will offer the New Shares under the Entitlement Offer without disclosure to Eligible Shareholders under Part 6D.2 of the Act.
- 2 As at the date of this notice, the Company has complied with:
  - (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
  - (b) section 674 of the Act.
- 3 As at the date of this notice there is no excluded information as defined in section 708AA(8) and section 708AA(9) of the Act which is required to be disclosed by the Company.
- 4 The potential effect the Entitlement Offer will have on the control of the Company, and the consequences of that effect will depend on the level of participation by Eligible Shareholders. However, given the structure of the Entitlement Offer as a pro-rata issue, the Entitlement Offer is not expected to have any material effect or consequences on the control of the Company.

## For more information, please contact:

Mr James McBrayer Managing Director, CEO and Company Secretary Cyclopharm Limited